# Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT

> **NCT01220297** · PHASE2 · TERMINATED · sponsor: **Stanford University** · enrollment: 3 (actual)

## Conditions studied

- Hematologic Diseases
- Acute-graft-versus-host Disease
- Leukemia
- Non-Hodgkin Lymphoma (NHL)
- Hodgkin Lymphoma

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Mycophenolate mofetil (MMF)
- **DRUG:** Carmustine
- **DRUG:** Etoposide
- **DRUG:** Cyclophosphamide (Cyclo, CY)
- **DRUG:** FTBI

## Key facts

- **NCT ID:** NCT01220297
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-08
- **Primary completion:** 2010-08
- **Final completion:** 2011-08
- **Target enrollment:** 3 (ACTUAL)
- **Why stopped:** Low accrual
- **Last updated:** 2017-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01220297

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01220297, "Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT01220297. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*